Supplementary Information

Engineering Af1521 improves ADP-ribose binding and identification of ADP-ribosylated proteins


Kathrin Nowak^{1, 2}, Florian Rosenthal¹, Tobias Karlberg³, Mareike Bütepage⁴, Ann-Gerd Thorsell³, Birgit Dreier⁵, Jonas Grossmann^{6, 7}, Jens Sobek⁶, Ralph Imhof¹, Bernhard Lüscher⁴, Herwig Schüler³, Andreas Plückthun⁵, Deena M. Leslie Pedrioli¹ and Michael O. Hottiger¹

¹Department of Molecular Mechanisms of Disease, University of Zurich, Switzerland ²Molecular Life Science PhD Program of the Life Science Zurich Graduate School, University of Zurich, Switzerland

³Department of Biosciences and Nutrition, Karolinska Institute, Huddinge, Sweden ⁴Institute of Biochemistry and Molecular Biology, RWTH Aachen University, Germany ⁵Department of Biochemistry, University of Zurich, Switzerland


⁶Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Switzerland ⁷SIB Swiss Institute of Bioinformatics, Quartier Sorge - Batiment Amphipole, Lausanne, Switzerland

Supplementary Figures 1 – 5



Supplementary Figure 1: Ribosome display evolves macro domain eAf1521


a Schematic illustration of the ribosome display selection cycle to evolve Af1521 macro domains with higher affinity towards ADP-ribosylation by selection with ADPr-modified H2B peptide (47). **b** Representation of the unmodified and modified H2B peptide that was synthetically ADP-ribosylated with a N-glycosidic linkage on Gln (Q) at position 2 of the peptide (47). c ELISA analysis of eAf1521 variants against the unmodified and ADPr H2B peptide. The ELISA was performed after the 4th round of errorprone PCR followed by selection using ribosome display. AU, absorbance unit. d Exemplary SDS-PAGE gel of pull-down experiment using unmodified and ADP-ribosylated H2B peptides (biotinylated and bound to streptavidin Sepharose beads) of Af1521 WT. The proteins were analyzed by SDS-PAGE followed by Coomassie staining. The whole SDS-PAGE gel confirms equal concentration of peptides are used and that the elution was sufficient for the binding assay. The experiment was repeated independently (n=3)with similar results. e Pull-down experiment using ADP-ribosylated H2B peptides (biotinylated and bound to streptavidin Sepharose beads) of WT Af1521 and eAf1521 under increasing ADPr concentration. The proteins were analyzed by SDS-PAGE followed by Coomassie staining. The experiment was repeated independently (n=2) with similar results. f Panel left: SPR sensorgrams for binding of ADPr (2500 – 39 nM) on immobilized WT Af1521. Panel right: Sensorgrams for binding of ADPr (25 - 6.25 nM) on immobilized eAf1521. g Demodification assay of radiolabeled automodified ARTD8cat. ADP-ribosylated ARTD8cat was detected by autoradiography. The experiment was repeated independently (n=2) with similar results. h View of the eAf1521 bound ADP-ribose around the ADP-ribose as well as side chains N34, E35 and R145 (omit map contoured at 1.5 σ). i Pull-down experiment using unmodified and ADPribosylated H2B peptides (biotinylated and bound to streptavidin Sepharose beads) of eAf1521, eAf1521-G42E and eAf1521-R145K. Input lanes are the same for all measured conditions. The proteins were analyzed by SDS-PAGE followed by Coomassie staining. The experiment was repeated independently (n=2) with similar results. Source data are provided as a Source Data file.



З


Supplementary Figure 2: Comparison of MS-based identification of ADP-ribosylated peptides and proteins using WT Af1521 or eAf1521

a Schematic drawing of the used MS workflow adapted form (26). **b** Volcano plot comparing ADPribosylated peptides in either untreated or H_2O_2 -treated HeLa cells lysate enriched with WT Af1521. The statistical analysis and *p*-value calculation was performed with two-tailed Student's *t*-test, the black lines represent foldchange > 2 and *p*-value < 0.05. **c** Venn diagram depicting the overlap of ADP-ribosylated protein groups in either untreated or H_2O_2 -treated HeLa cells enriched with WT Af1521. **d** Volcano plot comparing ADP-ribosylated peptides in either untreated or H_2O_2 -treated HeLa cells lysate enriched with eAf1521. **e** Venn diagram displaying the overlap of ADP-ribosylated protein groups in either untreated or H_2O_2 -treated HeLa cells enriched with eAf1521. The statistical analysis and *p*-value calculation was performed with two-tailed Student's *t*-test, the black lines represent foldchange > 2 and *p*-value < 0.05. **f** Venn diagram depicting the overlap of ADP-ribosylated proteins in H_2O_2 -treated HeLa cells lysate in different ADPr proteomic studies (27). For comparison with Hendriks et al. 2019 dataset only the closest experimental conditions Trypsin and EThcD were included. **g** Venn diagrams representing the biological replicates of ADP-ribosylated protein groups enriched with eAf1521 using different starting material (5 mg, 10 mg and 20 mg). Source data are provided as a Source Data file.




Supplementary Figure 3: Intensity of PSM is enhanced when ADP-ribosylated peptides are enriched with eAf1521

a Bar plot representing the number of identified ADPr PSMs in untreated and H_2O_2 -treated HeLa cell lysates enriched with either WT Af1521 or eAf1521. Data are presented as mean with SEM (*n*=3 biochemical independent samples). **b** Pie charts of all identified and ADPr PSMs in untreated and H_2O_2 -treated HeLa cell lysates enriched with either WT Af1521 or eAf1521. **c** Scatter plot depicting MS1 signal intensities of ADPr H2B peptide in untreated and H_2O_2 -treated HeLa cell lysates enriched with either WT Af1521 or eAf1521 or eAf1521 (*n*=3 biochemical independent samples). The statistical analysis and *p*-value calculation was performed with two-tailed Student's *t*-test (**p*<0.05, ns=not significant). Source data are provided as a Source Data file.



Supplementary Figure 4: Fc-WT Af1521 and eAf1521 as a tool for Western Blot analysis

a Schematic illustration of the generation of an ADP-ribosylation detection tool by fusing an Fc-fragment to WT Af1521 or eAf1521. b Dot blot analysis of purified Fc-WT Af1521 and Fc-eAf1521. The Fc fusion domains were detected using the His-tag. The experiment was repeated independently (n=2) with similar results. c Immunoblot analyses of untreated and H₂O₂-treated HeLa cells, including PJ34 treatment as control for ADP-ribosylation inhibition; unmodified, poly-ADP-ribosylated and mono-ADP-ribosylated ARTD1 and unmodified and mono-ADP-ribosylated ARTD8 with different concentrations of Fc-eAf1521 and Fc-WT Af1521. Detection was performed with IRDye 680 goat anti-mouse antibody. Immunoblot analyses to be compared were performed at the same time and with the same exposure. The experiment was repeated independently (n=2) with similar results. **d** Competition of Fc-WT Af1521 or Fc-eAf1521 with 1 µM ADPr in immunoblot analysis of unmodified, poly-ADP-ribosylated and mono-ADP-ribosylated ARTD1. Detection was performed with IRDye 680 goat anti-mouse antibody. Immunoblot analyses to be compared were performed at the same time and with the same exposure. The experiment was repeated independently (n=2) with similar results. **e** Dot blot analyses of free PAR chains with either Fc-eAf1521 or Fc-WT Af1521. Immunoblot analyses to be compared were performed at the same time and with the same exposure. Detection was performed with IRDye 680 goat anti-mouse antibody. The experiment was repeated independently (n=3) with similar results. **f** Immunoblot analyses of oligo-ADP-ribosylated and poly-ADP-ribosylated ARTD1 with either Fc-eAf1521 or Fc-WT Af1521. The automodification reaction of ARTD1 was performed with either 3 µM or 300 µM NAD+ for 30 min at 37°C. Immunoblot analyses to be compared were performed at the same time and with the same exposure. Detection was performed with IRDye 680 goat anti-mouse antibody. The experiment was repeated independently (n=2) with similar results. g Pull-down experiment using GST-Af1521 WT, GST-eAf1521 and GST of poly-ADP-ribosylated ARTD1. Only 10% of input and unbound fractions were loaded. The proteins were detected by immunoblot analysis stained with 10H antibody (PAR antibody) and followed by IRDye 680 goat antimouse antibody. The experiment was repeated independently (n=2) with similar results. Source data are provided as a Source Data file.



Supplementary Figure 5: Fc-WT Af1521 and Fc-eAf1521 as a tool for immunofluorescence analysis a Immunofluorescence analysis of H_2O_2 -treated HeLa cells with Fc-eAf1521 and Fc-WT Af1521. Detection was performed with an Alexa 488-labeled goat anti-mouse antibody. Signal intensity of Fc-WT Af1521 was set as background. Scale bar, 20 μ m. b Immunofluorescence analysis of H_2O_2 -treated HeLa cells with Fc-eAf1521 and Fc-WT Af1521, followed by Alexa 488-labeled goat anti-mouse antibody. Competition of Fc-WT Af1521 or Fc-eAf1521 with either 1 μ M ADPr or 1 μ M GTP. Scale bar, 20 μ m. c Immunofluorescence analysis of untreated or Olaparib-treated HeLa cells with Fc-eAf1521 and Fc-WT Af1521, followed by Alexa 488-labeled goat anti-mouse antibody. Af1521 and Fc-WT Af1521, followed by Alexa 488-labeled goat anti-mouse antibody. Af1521, followed by Alexa 488-labeled goat anti-mouse antibody. Af1521, followed by Alexa 488-labeled bar, 20 μ m. c Immunofluorescence analysis of untreated or Olaparib-treated HeLa cells with Fc-eAf1521 and Fc-WT Af1521, followed by Alexa 488-labeled goat anti-mouse antibody. Af1521, followed by Alexa 488-labeled bar, 20 μ m.